A durable response to cytarabine in advanced breast cancer

Clinical Oncology

Volumn 9, Issue 3, 1997, Pages 181-183

  Czaykowski, P M ^a   Samuels, T ^a   Oza, A ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Advanced breast cancer; Adverse drug events; Chemotherapy; Cytarabine

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUOROURACIL; HYALURONIC ACID; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; VINBLASTINE;

ACUTE LEUKEMIA; ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CASE REPORT; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PARTIAL MASTECTOMY; PRIORITY JOURNAL; SUPERIOR CAVA VEIN OBSTRUCTION;

EID: 0030818516     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(97)80077-5     Document Type: Article

References (14)

1. Chabner BA. Cytidine analogues. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice. 2nd ed. Philadelphia, PA: Lippincott-Raven, 1996:213-33.
2. Burke PJ, Owens AH, Colsky J, et al. A clinical evaluation of a prolonged schedule of cytosine arabinoside (NSC 63878). Cancer Res 1970;30:1512-5.
3. Davis HL, Rochlin DB, Wiess AJ, et al. Cytosine arabinoside toxicity and anti-tumor activity in human solid tumors. Oncology 1974;29:190-200.
4. Frei E, Bickes JN, Hewlett JS, et al. Dose schedule and anti-tumor studies of arabinosyl cytosine. Cancer Res 1969;29:1325-32.
5. Talley RW, O'Bryan RM, Tucker WG, et al. Clinical pharmacology and human anti-tumour activity of cytosine arabinoside. Cancer 1967;20:809-16.
6. Cummings FJ, Gelman R, Skeel RT. Phase II trials of Baker's antifol, bleomycin, CCNU, streptozotocin, tilorone, and 5-fluorodeoxyuridine plus arabinosyl cytosine in metastatic breast cancer. Cancer 1981;48:681-5.
7. Odujinrin O, DeConti RC, Bertino JR. Combination chemotherapy with cyclophosphamide, cytosine arabinoside, and methotrexate in advanced solid tumors. Cancer Chemother Rep 1975;59:1091-6.
8. Oster MW, Schilsky RL, Faraggi D, et al. Cytosine arabinoside and cisplatin for advanced breast cancer: A Phase II Study of the Cancer and Leukemia Group B. Cancer 1991;68:1696-8.
9. Vogel CL, Smalley RV, Raney M, et al. Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a 'cycle active' non-cross resistant combination in women with visceral metastatic breast cancer: A Southeastern Cancer Study Group project. J Clin Oncol 1984;2:643-51.
10. Feldman LD, Buzdar AU, Blumenschein GR. High-dose 1-beta-D-arabinofuranosylcytosine in advanced breast cancer. Oncology 1985;42:273-4.
11. Kaye SB. Gemcitabine: current status of Phase I and II trials [editorial]. J Clin Oncol 1994;12:1527-31.
12. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: Implications for prevention. JAMA 1995;274:29-34.
13. Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients: Results of the Harvard Medical Practice Study II. N Engl J Med 1991;324-84.
14. Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events. JAMA 1995;274:35-43.